CG
ECYT

Cutler Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Cutler Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-900
Closed -$8K – 5291
2018
Q1 		$8K Sell
900
-200
-18% -$1.1K ﹤0.01% 3007
2017
Q4 		$4K Buy
+1,100
New +$5.24K ﹤0.01% 3892
2017
Q3 		– Sell
-300
Closed – – 7200
2017
Q2 		$0 Sell
300
-22,237
-99% -$47.8K ﹤0.01% 7547
2017
Q1 		$57K Buy
22,537
+500
+2% +$1.16K ﹤0.01% 2288
2016
Q4 		$56K Buy
22,037
+20,839
+1,739% +$59.8K ﹤0.01% 2434
2016
Q3 		$3K Buy
1,198
+998
+499% +$3.11K ﹤0.01% 5547
2016
Q2 		$0 Buy
+200
New +$733 ﹤0.01% 7675

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's ECYT Position: Q2 2018 in Review

Cutler Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 900 shares — an estimated $8K sold.

Cutler Group first reported a position in ECYT in Q2 2016 and held it in 7 quarters. The position peaked at $57K in Q1 2017. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • Cutler Group reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Cutler Group sold 900 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $8K.
  • Cutler Group first reported a position in Endocyte, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
  • Cutler Group's Endocyte, Inc. Common Stock position peaked at $57K in Q1 2017.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.